Overview

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Status:
NOT_YET_RECRUITING

Trial end date:
2037-12-01

Target enrollment:

Participant gender:

Summary

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).

Phase:

PHASE3

Details

Lead Sponsor:

Eidos Therapeutics, a BridgeBio company

Treatments:

attruby